Assess drug efficacy against blood cancer progenitor cells.
We incubate diseased cells with your test compound(s) in a semi-solid, methylcellulose-based medium and we then assess cultures for changes in the number of cancer progenitor-derived colonies. We can also test your drug in a standard CFC assay to look for off-target toxicity to healthy donor progenitor cells.
Advantages:
Discovery’s expert cell biologists have developed numerous novel assays, enabling us to offer a broader and more strategic array of services to our clients. Our ongoing innovations accelerate drug discovery and development, ultimately enhancing patient outcomes.
Dr. Clarke has over 25 years of experience in stem cell biology, spanning both clinical and industrial settings. She plays a pivotal role in driving innovations and managing Discovery’s scientific operations, including research and development and client services. Dr. Clarke is also actively involved in client affairs, offering one-on-one consultations, study design, and data analysis.
The preclinical screening method that helps clients eliminate bad players earlier in the drug development process. White Paper
Colony Forming Cell assays can predict compound induced toxicities including neutropenia, thrombocytopenia, anemia and lymphotoxicity. Video
This in vitro assay has been validated by ECVAM (European Centre for the Validation of Alternative Methods) and correlates well with clinical neutropenia for many drug classes. Protocol
TIL Therapies Summit, Oct 22-24 Schedule a meeting with Conor during the 6th Annual TIL Therapies Summit Oct 22-24 | The Colonnade, Boston Conor Marino, Director of Business Development - […]
Join Discovery Life Sciences at World ADC 2024 November 4-7, 2024 | San Diego, California
Join Discovery Life Sciences at ASHG 2024 November 5-9, 2024 | Colorado Convention Center, Denver, Colorado
Copyright © 2024 Discovery Life Sciences. All rights reserved.
Designed & Developed by Altitude Marketing
